In this episode, Martin discusses why he believes parts of the biotechnology sector have entered a speculative bubble and explains the reasoning behind a controversial short position in a company developing a potential cancer treatment. He also analyzes Moderna and Capricor Therapeutics, examining their clinical programs, valuations, and investor expectations, before discussing Nvidia and the broader risks he sees across highly valued momentum stocks.
Podden och tillhörande omslagsbild på den här sidan tillhör
Urban Tapes. Innehållet i podden är skapat av Urban Tapes och inte av,
eller tillsammans med, Poddtoppen.
